Kidney cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Kidney cancer: OR 1.01 (95% CI 0.65 to 1.58), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
1 finding from 1 review
Body‐mass index (BMI) · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Body mass index: Z score -0.15 (95% CI -0.19 to -0.11), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review
Sporadic colorectal adenoma · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Sporadic colorectal adenoma: OR 0.82 (95% CI 0.69 to 0.97), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Type 2 diabetes (prevalent) · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Type 2 diabetes (prevalent): OR 0.45 (95% CI 0.25 to 0.82), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
All cause mortality · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality: HR 0.72 (95% CI 0.66 to 0.78), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Rectal cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for Rectal cancer: OR 0.50 (95% CI 0.29 to 0.88), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Colorectal cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 1,25(OH)2D) for Colorectal cancer: OR 1.01 (95% CI 0.59 to 1.73), not statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review
OR 1.01 [0.59, 1.73]
4 studies
GRADE not reported
Breast cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 1,25(OH)2D) for Breast cancer: OR 0.99 (95% CI 0.68 to 1.44), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Colon cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 1,25(OH)2D) for Colon cancer: OR 0.88 (95% CI 0.57 to 1.35), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
OR 0.88 [0.57, 1.35]
4 studies
GRADE not reported
Aggressive prostate cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 1,25(OH)2D) for Aggressive prostate cancer: OR 0.75 (95% CI 0.48 to 1.17), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
1 finding from 1 review
Prostate cancer · Adults (general population)
Meta-analysis of observational studies (higher vs lower 1,25(OH)2D) for Prostate cancer: OR 0.99 (95% CI 0.87 to 1.14), not statistically significant. Umbrella review outcome-level evidence grade: Substantial effect unlikely.
1 finding from 1 review
Small‐for‐gestational age · pregnant women and their infants..
Meta-analysis of observational studies (higher vs lower maternal 25(OH)D) for Small for gestational age: OR 0.54 (95% CI 0.44 to 0.67), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review